Biochem/physiol Actions

Target IC₅₀: 800 nM against cAMP-specific phosphodiesterase (PDE IV)

Reversible: no

Product does not compete with ATP.

Cell permeable: yes

Primary TargetPDE IV

General description

Cell permeable, selective competitive inhibitor of cAMP-specific phosphodiesterase IV (IC₅₀ = 800 nM). Rolipram does not inhibit PDE I or PDE II, even at concentrations as high as 100 µM. It is only a weak inhibitor of PDE III (IC₅₀ = 100 µM). A rolipram-insensitive phosphodiesterase IV subtype is also known to exist.

A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 800 nM). A rolipram-insensitive PDE IV subtype is also known to exist. Also inhibits NF-κB and NFAT activation in Jurkat and primary T cells.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Navarro, J., et al. 1998. J. Virol. 72, 4712.Truong, V.H. and Muller, T. 1994. FEBS Lett.353, 113.Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.Moore, J.B., Jr., et al. 1991. Biochem. Pharmacol.42, 679.Reeves, M.L., et al. 1987. Biochem. J. 241, 535.Schneider, H.H., et al. 1986. Eur. J. Pharmacol.127, 105.

Packaging

5 mg in Plastic ampoule

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Irritant (B)